Explore
Trendline
EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress
EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress
Read More
Trendline
EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials
EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials
Read More
Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Read More
Trendline
EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress
EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress
Read More
Trendline
Supernus Pharmaceuticals Reports Strong Revenue Growth Despite Earnings Miss
Supernus Pharmaceuticals Reports Strong Revenue Growth Despite Earnings Miss
Read More
Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Read More
Trendline
Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine
Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine
Read More
Trendline
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Read More
Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Read More
